Dr. Paddy Barrett
FEBRUARY 7, 2025
It is possible to reduce your risk of heart disease by over 90% 1. Let me show you how. But first, let’s get some facts straight. Over a long enough time frame, pretty much everyone will get heart disease. By the time you get to age 80, you will almost certainly have evidence of plaque in your coronary arteries - you will have heart disease. But remember: Heart disease doesn’t kill people.
Science Daily - Heart Disease
FEBRUARY 7, 2025
Women who have experienced pregnancy complications have an increased risk of cardiovascular disease. Now, a new study shows that sisters of women with complicated pregnancies are also at higher risk, even if they had uncomplicated pregnancies. The findings suggest that genes and shared environmental factors may influence the association between pregnancy complications and cardiovascular disease risk.
CardiacWire
FEBRUARY 7, 2025
It seems even interventional cardiologists arent immune to the Weekend Effect as a recent study suggests patients admitted on weekends for TAVR procedures face significantly higher risks. The “weekend effect” is a well-documented phenomenon in hospital care, often linked to reduced staffing levels, leading to potential delays in diagnosis and intervention.
HCPLive
FEBRUARY 7, 2025
More than 90% of patients with hemophilia B eliminated factor IX prophylaxis 4 years after treatment with etranacogene dezaparvovec (HEMGENIX) gene therapy.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
American Heart News - Stroke News
FEBRUARY 7, 2025
Research Highlights: In a randomized clinical trial in China, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms first appeared increased the odds of better recovery by 50% compared to those who received standard.
HCPLive
FEBRUARY 7, 2025
Investigators in Korea developed and validated PSED-FA, a reliable tool to assess parental confidence in managing children's food allergies and nutrition.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
FEBRUARY 7, 2025
Approved under the name dupixent in September 2024, the biologic is the first of its kind approved for COPD.
Science Daily - Heart Disease
FEBRUARY 7, 2025
In a randomized clinical trial, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms first appeared increased the odds of better recovery by 50% compared to those who received standard antiplatelet treatment.
HCPLive
FEBRUARY 7, 2025
GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.
Med Page Today
FEBRUARY 7, 2025
(MedPage Today) -- LOS ANGELES -- A course of transcranial direct current stimulation (tDCS) did not help with post-stroke motor recovery when tested in a larger multicenter randomized trial. Among stroke survivors 1-6 months out from their.
HCPLive
FEBRUARY 7, 2025
ADP101 raised food allergy thresholds in children but missed its primary endpoint. Findings support further research into multi-food oral immunotherapy.
Journal of Cardiothoracic Surgery
FEBRUARY 7, 2025
High levels of MG53 may attenuate the damage from myocardial infarction (MI). Furthermore, N6-methyl-adenosine (m6A) methylation is a mode of RNA modification that influences mRNA functions. Whether m6A modifi.
HCPLive
FEBRUARY 7, 2025
Emblaveo combines aztreonam, a monobactam antibiotic, and avibactam, a -lactamase inhibitor.
Med Page Today
FEBRUARY 7, 2025
(MedPage Today) -- LOS ANGELES -- For patients with large vessel occlusion (LVO) strokes, researchers found ways to make adjunctive intra-arterial (IA) thrombolytics work to improve outcomes after successful endovascular therapy (EVT), according.
HCPLive
FEBRUARY 7, 2025
Use of obinutuzumab was associated with significant improvements in complete renal response rate and markers of disease activity in active lupus nephritis.
All About Cardiovascular System and Disorders
FEBRUARY 7, 2025
Couple of chest X-rays showing serial changes in pulmonary hypertension over the years and another with features of severe pulmonary hypertension. The post Chest X-ray Features of Pulmonary Hypertension appeared first on All About Cardiovascular System and Disorders.
HCPLive
FEBRUARY 7, 2025
Panelists discuss how ensifentrine is a nebulized inhaled therapy, a small molecule inhibitor of PDE3 and PDE4, and is compelling because there are very few adverse effects. There are also compelling results from studies that show bronchial dilatation and exacerbation reduction.
Stroke: Vascular and Interventional Neurology
FEBRUARY 7, 2025
Stroke: Vascular and Interventional Neurology, Ahead of Print. BACKGROUNDNearly one fifth of the US population resides in rural areas. Although endovascular therapy can substantially improve clinical outcomes in patients treated with large vessel occlusion acute ischemic stroke, the penetration and outcomes of this therapy in rural US populations remain incompletely characterized.METHODSFrom the nationwide Get With The Guidelines Stroke registry, incorporating select social determinants of healt
HCPLive
FEBRUARY 7, 2025
These data suggest that the Family Acceptance and Commitment Therapy-based Eczema Management Program, or FACT-EMP, may be helpful to children with atopic dermatitis.
The American Journal of Cardiology
FEBRUARY 7, 2025
Publication date: Available online 6 February 2025 Source: The American Journal of Cardiology Author(s): Francesco Gallo, Ada Cutolo, Antonio Antonucci, Gabriele Cordoni, Elisabetta Demurtas, Andrea Panza, Sakis Themistoclakis
HCPLive
FEBRUARY 7, 2025
Findings from the VIVID-2 open-label extension study in patients with CD highlight long-term clinical and endoscopic outcomes with mirikizumab.
The American Journal of Cardiology
FEBRUARY 7, 2025
Publication date: Available online 7 February 2025 Source: The American Journal of Cardiology Author(s): Yudi Her Oktaviano, Ali Mustofa, Pandit Bagus Tri Saputra, Wynne Widiarti, Novia Nurul Faizah, Firas Farisi Alkaff
HCPLive
FEBRUARY 7, 2025
Interim analysis of the Phase 3 FRONTIER3 trial found Mim8 well-tolerated in children with hemophilia A with and without inhibitors.
Ken Grauer, MD
FEBRUARY 7, 2025
I was sent the ECG in Figure-1 without the benefit of any clinical information. QUESTIONS: What is the rhythm? How certain are you of your answer? Figure-1: The ECG I was sent. ( To improve visualization I've digitized the original ECG using PMcardio ). MY Thoughts on Making the Diagnosis: Rather than a "Yes-No" answer ( ie, Rather than saying the rhythm is VT vs SVT ) it is preferable to simply describe what you see.
HCPLive
FEBRUARY 7, 2025
The genetically edited pig kidney was provided by eGenesis and successfully transplanted into a 66-year-old male patient with end-stage kidney disease.
Physiologically Speaking
FEBRUARY 7, 2025
Greetings! Welcome to the Physiology Friday newsletter. Something to share: This week, I appeared as a guest on the FoundMyFitness podcast with Dr. Rhonda Patrick. We discuss how to train for aerobic fitness, muscle mass and strength, heart health, and more! You can find the full episode on YouTube or links to the podcast on other platforms here. Enjoy!
HCPLive
FEBRUARY 7, 2025
These data suggest that dupilumabs drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.
DAIC
FEBRUARY 7, 2025
tim.hodson Fri, 02/07/2025 - 10:41 Feb. 5, 2025 Removing a clot blocking a medium- or small-sized artery in the brain mechanically is a safe treatment for a common type of stroke; however, it did not lessen disability more than best medical treatment (including clot-busting medication if indicated) alone, according to preliminary late-breaking science presented at theAmerican Stroke Associations International Stroke Conference 2025 in Los Angeles.
HCPLive
FEBRUARY 7, 2025
Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.
Cassling
FEBRUARY 7, 2025
When Glenda was diagnosed with neuroendocrine tumors, her treatment options seemed limited. Learn how theranostics turned her life-threatening illness into a manageable, chronic condition, offering her a new path forward. For more than 15 years, 61-year-old Glenda suffered from severe, recurring abdominal pain. After repeated visits at doctors' offices and emergency rooms, a CT scan finally revealed the diagnosis: Glenda had neuroendocrine tumors.
DAIC
FEBRUARY 7, 2025
Getty Images tim.hodson Fri, 02/07/2025 - 11:01 Feb. 6, 2025 New findings from the DiVERT Stroke clinical study showed women spent less time in the hospital, saw fewer referrals to cardiology, and were prescribed less frequent post-stroke cardiac monitoring than men when admitted to comprehensive stroke centers following stroke. The data were presented at the International Stroke Conference (ISC) in Los Angeles.
Expert insights. Personalized for you.
104 
Let's personalize your content